NR3C2 and diabetic kidney disease: Moreover, finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has been shown to convey glycocalyx structure preservation by inhibition of matrix-metaloproteinase 2/9 activity in early diabetic nephropathy in diabetic rats [81].